Literature DB >> 22893488

Non-invasive determination of myocardial lipid content in Fabry disease by 1H-MR spectroscopy.

B Petritsch1, H Köstler, W Machann, M Horn, A M Weng, J P Goltz, D Hahn, M Niemann, F Weidemann, C Wanner, M Beer.   

Abstract

PURPOSE: In Fabry disease (FD), a progressive deposition of sphingolipids is reported in different organs. The present study applied 1H magnetic resonance spectroscopy (MRS) to investigate the myocardial lipid content in FD.
MATERIALS AND METHODS: In patients (PTS, n = 15) with genetically proven FD, 1H MRS of the heart was acquired in the same examination as routine cardiac cine and late enhancement MR imaging. Healthy volunteers (n = 11) without history of cardiac disease served as control (CTL). Myocardial triglycerides in vivo were quantified in 1H MRS. Left ventricular (LV) ejection fraction (EF) and late enhancement were assessed for the determination of LV systolic function, and onset or absence of myocardial fibrosis.
RESULTS: All 1H MRS revealed resonances for intramyocardial triglycerides. Clinical parameters, e.g. EF (PTS 64 ± 2 % vs. CTL 61 ± 1 %) were similar in PTS and CTL or showed a non-significant trend (LV mass). Apart from a single patient with elevated myocardial triglycerides, no significant impact of Fabry disease on the triglyceride/water resonance ratio (PTS 0.47 ± 0.11 vs. CTL 0.52 ± 0.11 %) was observed in our patient cohort.
CONCLUSION: A comprehensive cardiac evaluation of morphology, function as well as metabolism in Fabry PTS with suspected cardiac involvement is feasible in a single examination. No significant effect of myocardial triglyceride deposition could be observed in patients. The remarkably high myocardial triglyceride content in one patient with advanced FD warrants further studies in PTS with an extended history of the disease. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893488     DOI: 10.1055/s-0032-1313059

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  5 in total

Review 1.  Clinical use of cardiac PET/MRI: current state-of-the-art and potential future applications.

Authors:  Patrick Krumm; Stefanie Mangold; Sergios Gatidis; Konstantin Nikolaou; Felix Nensa; Fabian Bamberg; Christian la Fougère
Journal:  Jpn J Radiol       Date:  2018-03-10       Impact factor: 2.374

Review 2.  Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure.

Authors:  Waqas T Qureshi; Usama Bin Nasir
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

3.  Myocardial lipid content in Fabry disease: a combined 1H-MR spectroscopy and MR imaging study at 3 Tesla.

Authors:  B Petritsch; H Köstler; A M Weng; M Horn; T Gassenmaier; A S Kunz; F Weidemann; C Wanner; T A Bley; M Beer
Journal:  BMC Cardiovasc Disord       Date:  2016-10-28       Impact factor: 2.298

4.  Reduced Right Ventricular Native Myocardial T1 in Anderson-Fabry Disease: Comparison to Pulmonary Hypertension and Healthy Controls.

Authors:  Joseph J Pagano; Kelvin Chow; Aneal Khan; Evangelos Michelakis; Ian Paterson; Gavin Y Oudit; Richard B Thompson
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

5.  An investigation into potential gender-specific differences in myocardial triglyceride content assessed by 1H-Magnetic Resonance Spectroscopy at 3Tesla.

Authors:  Bernhard Petritsch; Herbert Köstler; Tobias Gassenmaier; Andreas S Kunz; Thorsten A Bley; Michael Horn
Journal:  J Int Med Res       Date:  2016-04-18       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.